19th European Congress on Alternatives to Animal Testing, September 20-23 2015, University of Linz, Austria

Preliminary program by sessions

(v. 17.09.2015)

Download the abstractbook here (high resolution, 58 mb). Or with a low resolution here (5 mb).

1.1 Multi-Organ-Chips I
Monday, 21 September 2015
    Six organ chip for substance toxicity testing using Homunculus platform
Dmitry Sakharov, RU-Moscow
    Pro-drug activation in a dynamic microfluidic systems interconnecting liver and tumor micro-tissues"
Jens Kelm, CH-Schlieren
    Mimicking the cyclic mechanical stress of the lung parenchyma in a breathing lung-on-chip
Janick Stucki, CH-Bern
1.2 Multi-Organ-Chips II
Monday, 21 September 2015
    Microfluidic in vitro platform for parallel human multi-tissue interaction studies
Jin-Young Kim, CH-Zurich
    Emulating the human vasculature in a multi-organ-chip platform
Tobias Hasenberg, DE-Berlin
    Cryopreserved human hepatocytes and IdMOC experimental system for the evaluation of human drug properties
Albert Li, US-Columbia MD
2 Stem Cells
Monday, 21 September 2015
    Geometrically confined cell differentiation and migration model for human teratogen detection
Jiangwa Xing, SG-Singapore
    Quantitative data on toxicant classification derived from transcriptomics studies of stem cell development
Marcel Leist, DE-Konstanz
    Vascular-like network enhances structural and functional maturation of human pluripotent stem sell derived cardiomyocytes in cardiovascular construct
Hanna Vuorenpää, FI-Tampere
    Human induced pluripotent stem cells as tools for studying the etiology of Non Alcoholic Fatty Liver Disease
James Adjaye, DE-Düsseldorf
    Differentiated human skin-derived stem cells as a novel cell source for in vitro screening of drug-induced liver injury (DILI)
Vera Rogiers, BE-Brussels
3.1 3D Models I
Sunday, 20 September 2015
    Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events
Ellen Fritsche, DE-Düsseldorf
    Stem-cell based in vitro models to study human CNS pathophysiology
Zeynab Nayernia, CH-Geneva
    The use of the 'Neurosphere-Assay’ to study specific disturbances on FGF-2 function during neurodevelopment
Marta Barenys, DE-Düsseldorf
    Assessment of the predictivity of neuronal networks coped to microelectrode arrays for identification of neurotoxicants
Tzutzuy Ramirez, DE-Ludwigshafen
    Advances in in vitro testing: the route to replace animal testing
Stella Homer, UK-Rotherham
3.2 3D Models II
Tuesday, 22 September 2015
    The HuALN model for testing immune reactivity in vitro
Christoph Giese, DE-Berlin
    Optimization of an eye irritation assay for hazard identification and labelling of materials to address the EU Cosmetic Directive and REACH Legislation
Yulia Kaluzhny, US-Ashland MA
    Versatile, polymer-based devices for multi-parameter in vitro toxicology
Roisin Owens, FR-Gardanne
    A microfluidics integrated electronic monitoring system of a 3D in vitro model of the renal tubule
Vincenzo Curto, FR-Gardanne
    Omnisphero: A novel computational approach for high content image analyses (HCA) of organoid neurosphere cultures in vitro
Martin Roland Schmuck, DE-Düsseldorf
4 International Progress in 3Rs' research & Global Cooperation on Implementing the 3Rs
Monday, 21 September 2015
    Beyond Europe: Accelerating regulatory uptake and use of 3R best practices globally
Troy Seidle, CA-Toronto
    EPAA - 10 years of progress and more to do
Renate Weissenhorn, BE-Brussels
    The Asian Congress on Alternatives and Animal Use in the Life Sciences 2016
Hajime Kojima, JP-Tokyo
    Transatlantic collaboration of Cosmetics Europe with NICEATM/ILS to assess and develop strategy for skin sensitisation safety assessment without animal testing
Sebastian Hoffmann, DE-Paderborn
    Decision Algorithm for 3R (Refine, Reduce, Replace) Programs - a case study in vaccines
Iwona Wilk-Zasadna, CH-Basel
paid advertising

Banner InSphero

5.1 QSAR & Read Across I - Read Across
Tuesday, 22 September 2015
    Preventing unnecessary testing by means of read-across: scope, justification and assessment
Karel de Raat, FI-Helsinki
    New tools to assist in the application of the read-across approach
Alessandra Roncaglioni,
    VPA Read across: Development of predictive biomarkers by using toxicity data of structurally similar compounds
Regina Stöber, DE-Hannover
    Metabolomics as a read across tool
Tzutzuy Ramirez
, DE-Ludwigshafen
5.2 QSAR & Read Across II - QSAR
Monday, 21 September 2015
    Use of (Q)SARs under REACH - perspective of a regulator
Matthias Herzler, DE-Berlin
    Application of in silico methods for predictions of different toxicological endpoints
Malgorzata Drwal, DE-Berlin
    QsarDB: solution strategy for efficient use of QSAR models
Uko Maran, EE-Tartu
    The Future of the QSAR Toolbox: moving to less uncertainty in predictive toxicology
Romualdo Benigni, IT-Roma
    Weighted gene co-expression network analysis to characterize drug induced cardiotoxicity
Jufeng Wang
, CN-Beijing
6 Risk assessment based on the AOP concept
Monday, 21 September 2015
    MIEs – the gateways to pathway prediction
Paul Russell, UK-Shambrook
    Integration of the epidemiological data with the experimental toxicity studies on pesticides; use of the AOP framework for the definition of biological plausibility
Andrea Terron, IT-Parma
    Characterization of the effects of epigallocatechin gallate (EGCG) exposure during neurodevelopment within the AOP concept
Marta Barenys, DE-Düsseldorf
    Applying Adverse Outcome Pathways to support Integrated Approaches to Testing and Assessment (IATA)
João Barroso, IT-Ispra
    Adverse Outcome Pathway Knowledge Base: A crowdsourcing tool to add value to existing information on Alternative Methods results
Clemens Wittwehr, IT-Ispra
7 Repeated Dose Toxicity & Other Toxicological Endpoints
Tuesday, 22 September 2015
    Towards the replacement of in vivo repeated dose systemic toxicity: Achievements of the SEURAT-1 research initiative
Tilmann Gocht, DE-Tübingen
    Metabolomics in vitro: a new approach for systemic toxicity – first applications for mode of action identification and chemical grouping
Tzutzuy Ramirez
, DE-Ludwigshafen
    28-day microphysiological monitoring of human hepatocellular cells
Joachim Wiest, DE-Munich
    Generation of the molecular basis for studying thyroid hormone disruption in neural progenitor cells of humans and rats
Susanne Giersiefer, DE-Düsseldorf
    Quantitative analysis of cell migration in the wound healing scratched assay by Using Active Contour Model and Speeded Up Robust Features
Melika Farshad, IR-Shiraz
    Failure and Success: in vitro ocular irritation test methods for agrochemical formulations the Bovine Cornea Opacity and Permeability Test and the EpiOcular™ Eye Irritation Test
Susanne Kolle, DE-Ludwigshafen
8 Inhalation
Tuesday, 22 September 2015
    Cellular human based systems for investigating the toxicity effects of inhalable substances
Samuel Constant, CH-Geneva
    Systems Toxicology-based assessment of aerosols using human organotypic tissue cultures of nasal and bronchial epithelium
Julia Hoeng
, CH-Lausanne
    Characterization of 3D reconstructed human airway models used for biomarker and inflammatory response studies
Rodger Curren, US-Gaithersburg MD
    Preliminary validation studies of a 3D in vitro inhalation model, using cytokine and gene expression responses to metal-oxide particles
Ingeborg Kooter, NL-Utrecht  
    Building a framework of communication between industry and regulators to identify in vitro methods suitable for tobacco regulatory science
Erin Hill, US-Gaithersburg MD
9.1 Skin Sensitization I
Sunday, 20 September 2015
    Outlook on currently available non-animal test methods for skin sensitization testing
Daniel Urbisch, DE-Ludwigshafen
    Reconstituted Human Epidermis Models and IL-18 Levels for Identification and Potency Ranking of Skin Sensitizers: Identification of Critical Steps and Harmonization of Existing Protocols for the Purpose of Validation
Erwin Roggen
, DK-Bagsvaerd
    Evaluating non-animal methods for identifying skin sensitisation hazards: A Bayesian value of information analysis
Maria Leontaridou, DE-Ludwigshafen
9.2 Skin Sensitization II
Tuesday, 22 September 2015
    Towards the assessment of skin sensitization potency: Quantitative estimations by the Direct Peptide Reactivity Assay
Susanne Kolle, DE-Ludwigshafen
    From pathways to people: Applying the skin sensitisation AOP to risk assessment
Gavin Maxwell
, UK-Shambrook
    Functional characterization of reconstructed skin containing in vitro generated Langerhans cells
Günther Weindl, DE-Berlin
    Evaluation of an in vitro human dermal sensitization test for use with medical device extracts
Jamin A. Sr. Willoughby, US-Kalamazoo MI
10.1 Efficacy & Safety Testing I
Tuesday 22 September 2015
    A relevant in vitro model for safety testing of chemicals and efficacy testing of pharmaceuticals
Tuula Heinonen, FI-Tampere
    Characterization of transporter activities in different cell types by using fluorescent substrates
Anett Ullrich, DE-Schwerin
    Development, optimization and standardization of an in vitro skin irritation test for medical devices using the reconstructed human tissue model EpiDerm
Helena Kandarova, SK-Bratislava
    HTS for screening of selective muscarinic cholinergic receptors antagonists
Valerii Tonkopii
, RU-St. Petersburg
10.2 Efficacy & Safety Testing II - Biological and Vaccines
Monday, 21 September 2015
    In vitro assays for the potency determination of botulinum neurotoxin serotypes A and B
Emina Wild, DE-Langen
    Avian encephalomyelitis live vaccines - alternative methods for batch virus titration
Lena Rimpel, DE-Langen
    Pro- and pre-hapten mechanisms in skin sensitization
David Roberts
, UK-Liverpool
    LLNA variability: an essential ingredient for a comprehensive assessment of non-animal skin sensitisation test methods and strategies
Sebastian Hoffmann
, DE-Paderborn
11 Nano-Toxicology
Monday, 21 September 2015
    Aligning nanotoxicology with the 3Rs: What is needed to realise the short, medium and long term opportunities?
Natalie Burden, UK-London
    NanoSafety research and its challenges!
Peter Wick, CH-St. Gallen
    Cytotoxic and immunological effects of engineered nanomaterials
Marika Mannerstrom, FI-Tampere
    Adressing inflammatory parameters of the intestinal mucosa: From the mouse to the test tube
Benno Weigmann, DE-Erlangen
    An advanced 3D human epithelial airway model to study the biokinetics of aerosolized biomedical nanoparticles after repeated exposures
Savvina Chortarea, CH-Fribourg
    Towards the prediction of nanoparticle-induced inhalation toxicity: Evaluation of an in vitro macrophage assay
Martin Wiemann, DE-Münster
    A decision-making framework for the grouping and testing of nanomaterials
Robert Landsiedel, DE-Ludwigshafen
paid advertising

12.1 Disease Models I: CRISPR/Cas
Sunday, 20 September 2015
    Scientific and animal welfare issues surrounding the new CRISPR/Cas-9 approach to produce transgenic animals and advanced in vitro disease models
Horst Spielmann, DE-Berlin
    CRISPR/Cas-induced structural variants
Malte Spielmann, DE-Berlin
    Paving the way to a novel analysis platform to study human diseases
Saniye Sprenger, DE-Berlin
    Modeling the air-blood-barrier in state of disease – challenges and perspectives
Marius Hittinger, DE-Saarbrücken
12.2 Disease Models II: hiPSC
Monday, 21 September 2015
    Reconstructed human skin pioneers the implementation of diversity into preclinical testing in vitro
Monika Schäfer-Korting
, DE-Berlin
    Human stem-cell based functional neuronal in vitro disease models
Susanna Narkilahti, FI-Tampere
    Alzheimer's disease research in the 21st century: the shift towards a new paradigm
Francesca Pistollato, US-Washington DC
    In vitro hiPSC-based modeling of late-onset disease using progerin-induced aging
Justine Miller, US-Rensselaer NY
12.3 Disease Models III: Inflammation
Wednesday, 23 September 2015
    Modular human biochip-based organoid models in sepsis research
Alexander Mosig, DE-Jena
    Use of ex vivo organotypic lung tissue in translational research of respiratory injury and inflammation diseases
Katherina Sewald, DE-Hannover
    Evaluation of selumetinib and trametinib MEK inhibitors antitumor efficacy in a preclinical in vitro human lung cancer model
Samuel Constant, CH-Geneva
    Phenotypic responses of human asthmatic airway epithelial cultures to rhinovirus and poly(I:C)
Patric Hayden, US-Ashland MA
    Small Airway-on-a-Chip: A novel human inflammatory disease model
Kambez Benam, US-Boston MA
13 Biobarriers
Wednesday, 23 September 2015
    Biophysical and metabolic properties of striae distensae evaluated ex vivo compared to normal skin
Youna Coquin, FR-Saint Gregoire
    Assess the bio-barrier function of the human respiratory system using an in vitro 3D model of airway epithelial model (MucilAir™)
Samuel Constant, CH-Geneva
    Intelligent inserts as scaffolds for functional cell co-culture models on a biomimetic scale
Silvia Angeloni, CH-Neuchâtel
    In vitro models of skin wounds – potential, limitations and perspectives
Maike Windbergs, DE-Saarbrücken
    Epithelial-endothelal co-cultures to mimic the air-blood-barrier
Brunhilde Blömeke, DE-Trier
    What happens when the particle has landed? – In vitro models for studying post-deposition events of aerosolized particles
Marius Hittinger, DE-Saarbrücken
14 EU Directive 2010/63/EU on the Protection of Animals Used for Scientific Purposes
Monday, 21 September 2015
    Directive 2010/63/EU: five years after its adoption
Herman Koeter, NL-Den Haag
    Non-technical summaries - a review of EU member states efforts so far
Katy Taylor, UK-London
    Different concepts of committees in EU member states, to support the competent authorities performing the project evaluation according to Directive 2010/63/EU
Norbert Alzmann, AT-Vienna
    The Role of the National Committee in Germany - Severity Assessment of Genetically Altered Animals
Bettina Bert, DE-Berlin
    Legal issues in the work of the German National Committee: an overview
Justyna Chmielewska, DE-Berlin
15.1 Ethics & Legal Issues I
Monday, 21 September 2015
    Pain for Profit. Can monetary reasons justify animal research ethically?
Herwig Grimm, AT-Vienna
    Evaluation of the scientific validity of animal experiments in Switzerland
Lucile Vogt, CH-Bern
    Implementing the 3Rs: turning words into action
Emily McIvor, UK-Seaton
15.2 Ethics & Legal Issues II
Tuesday, 22 September 2015
    Update on 3Rs activities at the EU institutional level and beyond the borders
Francois Busquet, BE-Brussels
    40 years of Animalfree Research. Results and lessons learned from a quality assessment      
Stefanie Schindler
, CH-Zurich
    Non-animal Testing: It’s within REACH
Julia Baines (replacing Gilly Stoddart), UK-Colchester
    REACH, the Cosmetics Regulation and upholding the animal testing ban
Julia Baines
, UK-Colchester
    Harm-benefit analysis of animal experimentation: a qualitative study of ethics committee practice in six European countries
Anna Olsson, PT-Porto
16.1 Refinement I and Culture of Care
Tuesday, 22 September 2015
    Working together to develop and implement a 'culture of care'
Kirsty Reid, BE-Brussels
    Pain Management and post-operative monitoring and care of laboratory rodents in Germany – lessons learnt and recommendations to improve practice
Kathrin Herrmann
, DE-Berlin
    Ending severe suffering: the scientific animal welfare organization as a catalyst for change
Elliot Lilley
, UK-Horsham
    Refinement facilitated by the Culture of Care
Susanna Louhimies
, BE-Brussels
16.2 Refinement II
Tuesday, 22 September 2015
    Barriers to the implementation of refinements in animal laboratories
Katy Taylor, UK-London
    Refinement strategies in experimental autoimmune encephalomyelitis (EAE) in mice
Kristina Ullmann, DE-Berlin
    Community guidelines on animal studies - ALS research as a case-study
Nuno Henrique Franco
, PT-Porto
    The role of the animal welfare officer on the 3R´s principle in laboratory animal science in Germany
Christa Thöne-Reineke
, DE-Berlin
    Ethics review of animal experiments in Europe under Directive 2010/63/EU
Anna Olsson
, PT-Porto
17.1 Replacement I
Tuesday, 22 September 2015
    Animals are not 'Materials and Methods': Why it is important to focus on Replacement
Candida Nastrucci, IT-Rome
    Examination of human bone tissue regeneration using the chorioallantoic membrane (CAM): an ex vivo replacement model for animal research
Ines Moreno
, UK-Southampton
    Strategies for combining skin and vasculature in a Multi-Organ-Chip Platform
Katharina Schimek, DE-Berlin
    Stem cell-derived human dorsal root ganglia-like cells to identify peripheral neurotoxicants
Lisa Hoelting
, DE-Konstanz
    Functional neurons from cancer cells: a novel in vitro model exhibits appropriate functional parameters
Susanna Alloisio, IT-Genoa
17.2 Replacement II
Tuesday, 22 September 2015
    3D biocompatibility test systems mimicking the in vivo situation: evaluation of a hydroxyapatite-nanoparticular paste
Veronika Hruschka
, AT-Vienna
    A mismatch between micro-motives and macro-behaviour: The inefficiency of efforts toward replacement at the individual level
Jan Lauwereyns
, JP-Fukuoka
    New guidance on information requirements for skin corrosion/irritation and serious eye damage/eye irritation under REACH
Bohumila Bichlmaier Suchanová
, FI-Helsinki
    Replacement – coming closer to a dream
Thomas Hartung, US-Baltimore MD
18.1 3Rs in Academia & Education I
Sunday, 20 September 2015
    The Berlin-Brandenburg Research Platform BB3R and integrated graduate school
Monika Schäfer-Korting, DE-Berlin
    CERST-NRW: a German state government of North Rhine Westphalia-funded initiative for the development of alternative methods to animal testing
Ellen Fritsche, DE-Düsseldorf
    Teaching alternative methods in toxicology in veterinary science
Francesca Caloni, IT-Milano
    Romanian Center for Alternative Test Methods (ROCAM) – a newly established 3Rs Center to promote and support the alternative methods field in Romania
Lucian Farcal, RO-Cluj-Napoca
    CAAT-Europe and knowledge exchange on the progress of the 3Rs and research methods
Marcel Leist, DE-Konstanz
18.2 3Rs in Academia & Education II
Monday, 21 September 2015
    Reboot3R - Design Thinking Workshops for scientists to constructively find ways to apply 3Rs within their own career
Cecilia Hilmer, DE-Berlin
    Animal Research: critical, challenging & creative thinking about the 3Rs
Juliet Dukes, UK-Southwater
    A Course in Alternatives: focus on replacement and non-animal methods
Candida Nastrucci, IT-Rome
    Follow-up on 2013 EUSAAT’s Congress and its impact for Sri Lankan scientific community in 3Rs
Mangala Gunatilake, LK-Colombo
    Improving animal welfare through competence: The EUPRIM-Net education and training programs
Valeska Marija Stephan, DE-Göttingen
    Refinement of welfare through application of a quantitative system for assessment of lifetime experience
Michael Dennis
, UK-Salisbury
    Journal policies on animal use – current landscape and future directions
Nuno Henrique Franco, PT-Porto
19.1 Young Scientists Short Lectures I
Tuesday, 22 September 2015
    A 3D in vitro iPSC derived mini-brain model to study Parkinson’s disease
David Pamies, US-Baltimore MD
    Molecular modelling of osteoarthritis – evaluating pathways in vitro
Annemarie Lang, DE-Berlin
    A novel human organotypic tumor invasion model of cell line MDA-MB-231 in Precision-Cut Lung Slices (PCLS) to reduce animal experiments in preclinical oncology
Sebastian Konzok, DE-Hannover
    Impaired skin barrier function of cutaneous squamous cell carcinoma
Christopher Wolff, DE-Berlin
    Generation of 3D neurospheres from human induced pluripotent stem cells as an alternative in vitro method to study neurodevelopmental defects of Cockayne Syndrome patient
Maxi Hofrichter, DE-Düsseldorf
    Human lymphoblastoid cell lines as an in vitro tool in preclinical drug evaluation
Tijana Markovic, SI-Ljubljana
    Systematic assessment of different computational approaches for prediction of toxic effects of new chemical structures
Priyanka Banerjee
, DE-Berlin
19.2 Young Scientists Short Lectures II
Wednesday, 23 September 2015
    Chip-based co-culture of neurospheres and liver spheroids for long-term substance testing
Anja Ramme, DE-Spreenhagen
    Human in vitro Blood-Brain Barrier model generated from stem cells: reducing attrition in the Central Nervous System area
Aurore Drolez, FR-Lens
    A microfluidic four-organ-chip – a potential tool for ADME profiling
Juliane Hübner, DE-Berlin
    In vitro investigation on uptake, cytotoxicity and genotoxicity of two similar sized titanium oxide nanoparticles on the human hepatic cells HepaRG
Pegah Jalili, FR-Fougeres
    Optimization of a new in vitro method for inhalation toxicology and its application for the study of zinc oxide nanoparticle toxicity
Emilie Da Silva, DK-København
    Assessment of sensitization and photosensitization of benzophenone-3 based on DPRA
Carolina Benevenuto, BR-Brazil

For the session finder - click HERE
Download the session finder as pdf HERE